Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention
Treatment cessation due to adverse events · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in adverse events requiring cessation of study drug(s) compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
- Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes onlyRR 0.89 [0.62, 1.27]11 studies · 1691 participantsLow